Published: 2013 05 01 at 14:57
Reporters from the Hunan Nonferrous Chembrane Bio-Pharmaceutical Co., Ltd. was
informed that, in early April the company approved anti-bird flu drug
peramivir has passed the GMP (Good Manufacturing quality standards)
certification, but there is no production schedule.
Early last month, in response to human infection with the H7N9 avian
flu, the State Food and Drug Administration and the Drug Evaluation
Center rapid deployment and approved by China's independent research and
development of new drugs to market peramivir. In accordance with the relevant procedures, peramivir passed GMP certification, can be put into production.
However the Hunan Nonferrous Chembrane responsible for people, told
reporters that peramivir exactly when production is planned to study and
then set according to market conditions.